Arkin Bio Capital
Overview
Arkin Bio Capital is a venture capital fund that focuses on late-stage investments in global biotech and pharmaceutical companies, particularly those developing innovative medicine and planning to go public.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Nocion Therapeutics | Jan 2026 | Series B Extension | Lead |
| Crossbow Therapeutics | Mar 2026 | Series B | Lead |
| Reunion Neuroscience Inc. | Sep 2025 | Series A Extension | Co-investor |
| NextPoint Therapeutics | Feb 2024 | Series B Extension | Co-investor |
| Newleos Therapeutics | Feb 2025 | Series A | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Arkin Bio Capital based?
Arkin Bio Capital is headquartered in Herzliya, Israel.
When was Arkin Bio Capital founded?
Arkin Bio Capital was founded in 2021.
How many portfolio companies does Arkin Bio Capital have?
Arkin Bio Capital has 6 portfolio companies in Caplight's dataset.
What are some companies in Arkin Bio Capital's portfolio?
Portfolio companies visible on Caplight include Nocion Therapeutics, Crossbow Therapeutics, Reunion Neuroscience Inc., NextPoint Therapeutics, Newleos Therapeutics.
What was Arkin Bio Capital's most recent investment shown here?
Arkin Bio Capital's most recent investment in this portfolio sample was in Crossbow Therapeutics in 2026.
What sectors does Arkin Bio Capital focus on?
Arkin Bio Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Arkin Bio Capital focus on?
Arkin Bio Capital typically invests at the Mid stage.
What is Arkin Bio Capital's AUM?
Arkin Bio Capital's assets under management are estimated at over $2.0B.